FDA Grants Orphan Drug Status to Pulmonary Arterial Hypertension Treatment
ZMA001, in development for pulmonary arterial hypertension, has been designated as an Orphan Drug by the US Food and Drug Administration.
Tag: CTEPH PAH and pulmonary hypertension
All
Latest
All
Latest
Janssen Submits New Drug Application for Investigational Single-Tablet Combo Therapy to Treat PAHÂ
The Janssen Pharmaceutical Companies of Johnson & Johnson is seeking FDA approval of an investigational single-tablet combination therapy of macitentan and tadalafil for the long-term treatment of pulmonary arterial hypertension.
All
Latest
Pulmonary Hypertension Guidelines Call for Earlier Diagnosis
Earlier detection of pulmonary hypertension in the community and expedited referral of high-risk or complex patients are recommended in the new ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.
COPD Phenotyping Can Help Manage Pulmonary Hypertension
Patients with pulmonary hypertension and chronic obstructive pulmonary disease can now be identified by looking at three clinical variables, new research shows.
Read More
Sleep Apnea Common in Pulmonary Hypertension
A recent study highlights the importance of treating pulmonary hypertension in patients with obstructive sleep apnea.
Read More
Higher Blood Pressure Levels During COVID-19 Pandemic
The COVID-19 pandemic is associated with higher blood pressure levels among middle-aged adults across the US, according to research published in the journal Circulation.
Read More
Inhaled Nitric Oxide in Cardiovascular Surgery for Perioperative Pulmonary Hypertension: A Review
Clinical trial and real-world data provide evidence that inhaled nitric oxide is effective for reducing pulmonary hypertension in the perioperative setting.Â
Read MoreCVS Offers New Care Management Program for Pulmonary Arterial Hypertension
A CVS subsidiary launched a program to help patients with pulmonary arterial hypertension (PAH) better manage their own care.
Read More
Pulmonary Hypertension May Raise Kidney Failure Risk For Certain Patients
Patients who have chronic kidney disease and pulmonary hypertension are at a greater risk for a variety of adverse outcomes, according to new research.
Read MoreStudy: Iron Supplements and Pulmonary Arterial Hypertension
Can patients with pulmonary arterial hypertension and iron deficiency benefit from iron supplements?
Read More
Study: Surgery Outcomes for Segmental Chronic Thromboembolic Pulmonary Hypertension
A new study, presented at the American Association for Thoracic Surgery’s annual meeting, found that patients treated surgically for segmental chronic thromboembolic pulmonary hypertension had positive outcomes.
Read More
Study: Pulmonary Hypertension in Patients With Pulmonary Fibrosis
A new literature review looks at the role of pulmonary hypertension in people with pulmonary fibrosis.
Read More
Pulmonary Hypertension Patients Exhibited Reduced Exercise Capacity Under Hypoxia
Results of a clinical trial show that patients with pulmonary hypertension (PH) have a lower capacity for exercise during hypoxia.
Read More
Study Evaluates The Benefits of Inhaled Nitric Oxide in Pulmonary Hypertension
High dose inhaled nitric oxide resulted in improvements in physical activity and other outcomes in patients at risk for pulmonary hypertension-associated fibrotic interstitial lung disease.
Read More
Pulmonary Vascular Resistance in Pulmonary Hypertension and Mortality Risk
A new study sheds light on the range of pulmonary vascular resistance associated with mortality and heart failure in certain patients at risk for pulmonary hypertension.
Read More